Tandklinikken CS ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  11.6% 8.0% 4.3% 5.5% 6.9%  
Credit score (0-100)  22 30 46 41 34  
Credit rating  BB BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  171 201 734 1,035 790  
EBITDA  63.6 118 168 116 1.7  
EBIT  49.4 85.8 112 54.1 -60.4  
Pre-tax profit (PTP)  47.9 82.5 104.4 48.2 -60.3  
Net earnings  36.4 63.6 79.3 36.2 -46.5  
Pre-tax profit without non-rec. items  47.9 82.5 104 48.2 -60.3  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  115 149 243 181 119  
Shareholders equity total  86.4 150 229 265 219  
Interest-bearing liabilities  90.0 91.6 94.0 108 18.0  
Balance sheet total (assets)  208 315 423 485 361  

Net Debt  45.4 91.5 -37.5 -146 -139  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  171 201 734 1,035 790  
Gross profit growth  0.0% 17.6% 264.5% 40.9% -23.7%  
Employees  0 0 0 0 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  208 315 423 485 361  
Balance sheet change%  0.0% 51.4% 34.3% 14.5% -25.5%  
Added value  63.6 117.9 167.5 109.5 1.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  100 2 39 -124 -124  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  28.9% 42.6% 15.3% 5.2% -7.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  23.7% 32.8% 30.4% 11.9% -14.3%  
ROI %  27.4% 40.1% 38.7% 15.2% -19.6%  
ROE %  42.1% 53.8% 41.8% 14.6% -19.2%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  41.5% 47.6% 54.2% 54.8% 60.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  71.3% 77.6% -22.4% -125.6% -7,932.3%  
Gearing %  104.2% 61.0% 41.0% 40.7% 8.2%  
Net interest  0 0 0 0 0  
Financing costs %  3.3% 3.6% 8.4% 5.8% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.5 0.8 0.7 1.2 1.3  
Current Ratio  0.5 0.8 0.7 1.2 1.3  
Cash and cash equivalent  44.6 0.0 131.5 254.0 156.7  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -55.7 -25.3 -53.8 41.1 44.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 1  
EBIT / employee  0 0 0 0 -30  
Net earnings / employee  0 0 0 0 -23